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 Herd protection induced by pneumococcal conjugate vaccine
Why is herd protection from pneumococcal disease 
important? The pneumococcus is the leading cause of 
death in children worldwide,1 and children who die are 
likely to be those who are unable to access lifesaving 
antibiotics and pneumococcal conjugate vaccine 
(PCV). However, if vaccination of other children in the 
community stops transmission of the serotypes in the 
vaccine, then protection is provided to those most at 
risk of mortality, even if they are not given the vaccine 
themselves. The immunisation of infants with PCV in 
developed countries extends protection beyond direct 
protection of the immunised infants, to include children 
too young to be immunised,2 adults with substantial risk 
of pneumococcal disease such as those infected by HIV,3 
and older people.4 Indeed, the cost-eﬀ ectiveness of PCV 
is such that in developed countries, despite the high cost 
of the vaccine, herd protection means use of the vaccine 
is cost saving.5 More than 90% of hospital admissions 
averted by the vaccine in developed countries occur in 
unimmunised adults,4 who are indirectly protected by 
the cessation of transmission to them of the serotypes 
in the vaccine.
Do these herd beneﬁ ts exist in developing countries 
and how best can we study herd protection in settings 
that do not have microbiological conﬁ rmation of 
invasive pneumococcal disease, much less the serotyping 
of isolated strains, and also do not have electronic 
International Classiﬁ cation of Diseases to record 
pneumonia hospital admissions and deaths? The ﬁ rst 
part of the question—do herd beneﬁ ts exist in developing 
countries—is being answered by a series of reports that 
consistently suggest that the rollout of PCV in Africa 
seems to be associated with reductions in transmission 
of vaccine-type pneumococci in the community. In a trial 
of 7-valent PCV (PCV7) in The Gambia,6 and after PCV7 
rollout in a 6-week, 14-week, and 9-month schedule in 
rural South Africa,7 reductions in carriage of vaccine types 
were found in unimmunised children and adults in the 
community. In The Lancet Global Health Laura Hammitt 
and colleagues8 extend these data to PCV10 and show 
that in the coastal demographic surveillance area around 
Kiliﬁ , Kenya, where PCV10 was introduced in January, 
2011, a reduction in nasopharyngeal carriage of vaccine 
serotypes occurred not only in immunised children, but 
also in unimmunised children and adults over the next 
2 years. To speed up the prospect of herd protection 
from PCV10 in the area, children younger than 5 years 
were oﬀ ered the vaccine.8 Carriage of vaccine types 
was reduced by 66% (95% CI 38–82) in unimmunised 
children and adults at least 5 years old. Was the catch-
up immunisation of children 12–59 months old the key 
to the rapid appearance of herd protection in older age 
groups? A similar level of reduction in carriage (61%) 
among unvaccinated children 1–5 years old was noted 
in the same 2 years after PCV10 introduction in Kenya 
without catch-up, in an urban slum,9 suggesting that 
perhaps the key vaccine-type pneumococcal transmitters 
are probably younger than 2 years.
Detailed data were available in Kiliﬁ  not only on 
carriage of vaccine types of pneumococci, but also on 
receipt of vaccine by the individuals in the study, and 
the overall vaccine coverage in the community was 
also known. The data suggest that vaccine coverage 
of around two-thirds of children younger than 5 years 
was suﬃ  cient to induce herd protection. This number is 
similar to the estimate of coverage of children (65–75%) 
needed to induce herd protection to PCV13 in Boston 
(MA, USA).10
More data are needed in many developing countries 
before we can be conﬁ dent about the coverage needed 
to induce herd protection in those settings. We need 
to know the number of immunisations that need to 
be given and their timing; the extent to which urban 
settings diﬀ er from rural; the eﬀ ect, if any, of HIV 
infection in adults (particularly mothers) and infants 
on transmission; how herd protection shows patterns 
of social mixing; the role of carriage in adults; the 
importance of pneumococcal density for transmission; 
the role of serotype and viral infections in transmission; 
and the diﬀ erences, if any, between PCV10 and PCV13 in 
induction of herd protection.
A modiﬁ cation of the approach in the Massachusetts 
study10 suggests a reasonable way forward to measure 
herd protection from vaccine-type pneumonia in 
developing countries. In this study, children were 
recruited and swabs taken when they attended a 
paediatric practice for any reason as the vaccine was 
rolled out in the state. Records were kept on the 
vaccination status of each child who was swabbed. 
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clinic or hospital in a developing country with signs and 
symptoms of pneumonia could have a nasopharyngeal 
swab taken and their vaccination status recorded 
from the time the vaccine is rolled out in the country. 
This method would allow the detection of carriage 
of invasive serotypes such as 1, 4, 5, and 7F, which are 
rarely found in carriage among healthy children. It 
would also provide data to calculate both the point in 
time and the rate of vaccine coverage at which carriage 
of vaccine-type pneumococci in unimmunised children 
with pneumonia equals that in the immunised children, 
which is the very point at which herd protection is 
induced.
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